Journal of Obesity and Metabolism
Open Access

Anorexiants; Appetite suppressants; Weight management; Mechanisms of action; Clinical efficacy; Pharmacological treatment

Introduction

Obesity remains a major global health challenge, significantly contributing to the burden of chronic diseases such as Type-2 diabetes, cardiovascular disease, and certain cancers [1]. While lifestyle modifications including diet and physical activity are foundational for managing obesity, these approaches often fall short for many individuals, necessitating additional interventions. Among these, anorexiants, or appetite suppressants, have emerged as a key pharmacological strategy to support weight management. Anorexiants are designed to assist in weight loss by influencing appetite regulation. They achieve this through various mechanisms, including altering neurotransmitter levels that control hunger and satiety. Commonly targeted neurotransmitters include norepinephrine, serotonin, and dopamine, each playing a role in appetite control and energy balance [2]. By modifying these pathways, anorexiants can help individuals adhere to calorie-restricted diets and achieve more significant weight loss.

The clinical application of anorexiants has evolved over time, with several medications gaining approval for use in obesity management [3]. However, their effectiveness and safety profiles vary, and they are often used in conjunction with lifestyle interventions to optimize outcomes. The balance between benefits and potential risks, such as cardiovascular effects, psychological impacts, and long-term safety, is crucial in determining their role in a comprehensive weight management plan. This paper aims to provide a detailed examination of anorexiants, focusing on their mechanisms of action, efficacy, and clinical applications. By reviewing current research and clinical data, we aim to highlight the potential benefits and limitations of these medications in obesity treatment. Understanding these aspects is essential for healthcare providers to make informed decisions about integrating anorexiants into patient care and to guide future research and development in this field. In summary, anorexiants represent a significant tool in the management of obesity, offering potential benefits for individuals struggling to achieve weight loss through lifestyle changes alone [4]. A comprehensive understanding of their mechanisms, efficacy, and clinical use is vital for optimizing their application and improving patient outcomes in weight management.

Results and Discussion

Most anorexiants, such as phentermine and sibutramine (historically), work by increasing the levels of norepinephrine and serotonin in the brain. This increase helps reduce appetite by enhancing satiety signals and reducing hunger [5-7]. Medications like buproprion affect dopamine levels, which can influence mood and appetite. This mechanism is particularly relevant in treatments targeting both obesity and depressive symptoms. Some newer anorexiants interact with hormones such as ghrelin and leptin, which play crucial roles in hunger and energy expenditure. For example, GLP-1 receptor agonists like liraglutide mimic the effects of the gut hormone GLP-1 to enhance satiety and promote weight loss. Clinical trials have demonstrated that anorexiants can lead to significant weight loss. For instance, medications like orlistat and phentermine-topiramate have shown average weight reductions of approximately 5-10% of initial body weight over a 12-month period [8]. In addition to weight loss, anorexiants have been associated with improvements in metabolic parameters, such as reduced blood glucose levels and lower cholesterol levels. This can contribute to better overall health and reduced risk of obesity-related comorbidities. Some anorexiants show superior efficacy compared to others. For example, combined therapies like phentermine-topiramate and buproprion-naltrexone tend to offer more significant weight loss compared to single-agent treatments. Certain anorexiants, such as fenfluramine and dexfenfluramine (withdrawn due to cardiac issues), have been associated with cardiovascular risks, including hypertension and heart valve abnormalities. Current medications are generally safer but may still pose risks for individuals with pre-existing conditions. Some anorexiants can lead to psychological side effects such as anxiety, insomnia, and mood changes. These effects are particularly noted with medications affecting neurotransmitter levels [9]. Long-term safety data is still evolving. Most modern anorexiants, such as GLP-1 receptor agonists, have demonstrated a favorable safety profile in long-term studies, but ongoing monitoring is necessary to identify any emerging concerns.

The diverse mechanisms of action among anorexiants reflect their varying impacts on weight management. Medications targeting neurotransmitter systems typically provide a more immediate effect on appetite, whereas those interacting with hormonal pathways may offer additional metabolic benefits. Understanding these mechanisms helps tailor treatment to individual patient needs, improving the likelihood of successful weight management. Anorexiants are most effective when used as part of a comprehensive weight management plan, including lifestyle changes such as diet and exercise. Combining pharmacological treatment with behavioral interventions maximizes the potential for achieving and maintaining weight loss. Personalized treatment plans are crucial. Factors such as the patient’s health profile, potential side effects, and specific weight loss goals should guide the selection of an appropriate anorexiant. Ongoing research is focused on developing new anorexiants with enhanced efficacy and safety profiles. Novel drugs that target different pathways or combine multiple mechanisms may offer improved outcomes [10]. Exploring combinations of anorexiants with other therapeutic modalities, such as behavioral therapies or different classes of medications, could provide synergistic benefits and better weight management results. Continuous monitoring and research are essential to assess the long-term safety and effectiveness of existing and new anorexiants. Longitudinal studies will help address concerns related to chronic use and identify any latent adverse effects. In conclusion, anorexiants can significantly aid in weight management by reducing appetite and facilitating weight loss. Their efficacy and safety profiles vary depending on the specific medication and individual patient factors. Continued research and careful clinical application are necessary to optimize their use and address any associated risks. Integrating anorexiants with comprehensive weight management strategies offers the best chance for achieving sustained weight loss and improving overall health outcomes.

Conclusion

Anorexiants represent a valuable component of the pharmacological arsenal for managing obesity, providing significant benefits for individuals who struggle to achieve adequate weight loss through lifestyle modifications alone. These appetite suppressants work through various mechanisms, such as modulation of neurotransmitters and hormonal pathways, to effectively reduce appetite and support weight management efforts. The efficacy of anorexiants has been well-documented in clinical trials, demonstrating their ability to produce notable weight loss and improve related metabolic parameters. Medications like phentermine-topiramate and GLP-1 receptor agonists have shown promise in achieving substantial weight reductions and enhancing overall health outcomes. However, the effectiveness of these treatments can vary, and their success often depends on individual patient characteristics and adherence to comprehensive treatment plans that include lifestyle changes. Despite their benefits, anorexiants are associated with potential risks, including cardiovascular side effects, psychological effects, and long-term safety concerns. Modern anorexiants have generally improved safety profiles compared to older medications, but careful monitoring and individualized treatment plans are crucial to mitigate these risks. Future directions in anorexiant research should focus on developing novel compounds with improved efficacy and safety profiles, exploring combination therapies, and continuing long-term safety evaluations. By addressing current limitations and integrating anorexiants with other therapeutic strategies, healthcare providers can enhance the effectiveness of obesity management and offer better outcomes for patients. In summary, anorexiants can be an effective tool in the management of obesity when used appropriately within a broader weight management strategy. Their role in facilitating weight loss and improving health outcomes underscores the importance of ongoing research and careful clinical application. By advancing our understanding of these medications and optimizing their use, we can better support individuals in achieving sustainable weight loss and improving overall health.

Acknowledgement

None

Conflict of Interest

None

References

1. Zhang J, Chen H, Kornreich R, Yu C (2019) Prenatal Diagnosis of Tay-Sachs Disease. Methods Mol Biol 1885: 233-250.

Indexed at, Google Scholar, Crossref

2. Bomberg EM, Ryder JR, Brundage RC, Straka RJ, Fox CK, et al. (2019) Precision medicine in adult and pediatric obesity: a clinical perspective. Ther Advs in Endocrinol and Metab 10: 2042018819863022.

Indexed at, Google Scholar, Crossref

3. Christison AL, Daley BM, Asche CV, Ren J, Aldag JC, et al. (2014) Pairing motivational interviewing with a nutrition and physical activity assessment and counseling tool in pediatric clinical practice: a pilot study. Child Obes 10: 432-441.

Indexed at, Google Scholar, Crossref

4. Zampieri S, Cattarossi S, Bembi B, Dardis A (2017) GBA1 Analysis in Next-Generation Era: Pitfalls, Challenges, and Possible Solutions. J Mol Diagnost 19: 733-741.

Indexed at, Google Scholar, Crossref

5. Yoshida S, Kido J, Matsumoto S, Momosaki K, Mitsubuchi H, et al. (1990) Prenatal diagnosis of Gaucher disease using next-generation sequencing. Pediatr Int 58: 946-949.

Indexed at, Google Scholar, Crossref

6. Dawson AM, Brown DA, Cox A, Williams SM, Treacy L, et al. (2014) Using motivational interviewing for weight feedback to parents of young children. J Paediatr Child Health 50: 461-470.

Indexed at, Google Scholar, Crossref

7. Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC, et al. (2018) Prevalence of Obesity and Severe Obesity in US Children, 1999-2016. Pediatrics 141: e20173459.

Indexed at, Google Scholar, Crossref

8. Korlach J, Bjornson KP, Chaudhuri BP, Cicero RL, Flusberg BA, et al. (2010) Real-time DNA sequencing from single polymerase molecules. Methods Enzymol 472: 431-55.

Indexed at, Google Scholar, Crossref

9. Ibach J, Brakmann S (2017) Sequencing single DNA molecules in real time. Angew Chem Int Ed Engl 48: 4683-5.

Indexed at, Google Scholar, Crossref

10. Bean MK, Thornton LM, Jeffers AJ, Gow RW, Mazzeo SE, et al. (2019) Mazzeo.Impact of motivational interviewing on engagement in a parent-exclusive paediatric obesity intervention: randomized controlled trial of NOURISH+MI. Pediatr Obes 14: e12484.

Indexed at, Google Scholar, Crossref